These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 15485737)

  • 1. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.
    Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L
    N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V; Naylor CD
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the use of t-PA as compared with streptokinase cost effective?
    Armentano R; Favaloro RG
    N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
    Kaul P; Armstrong PW; Chang WC; Naylor CD; Granger CB; Lee KL; Peterson ED; Califf RM; Topol EJ; Mark DB
    Circulation; 2004 Sep; 110(13):1754-60. PubMed ID: 15381645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the use of t-PA as compared with streptokinase cost effective?
    Rose EA
    N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
    Lessler DS; Avins AL
    Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the cost effectiveness of treatment of acute myocardial infarct with primary angioplasty and thrombolysis ].
    Golán L; Simek S; Linhart A; Cahlík T; Palecek T; Lubanda JC; Korínek J; Beran S; Aschermann M
    Vnitr Lek; 2003 Feb; 49(2):97-102. PubMed ID: 12728575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
    Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
    Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
    Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
    Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An economic evaluation of low dose recombinant human tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism].
    Wu YQ; Tao LB; Lü C; Hu YH
    Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):103-6. PubMed ID: 20356492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myocardial infarction treated within 4 hrs: comparison of the cost-benefit ratio of 3 thrombolytic treatments: APSAC, rt-PA and streptokinase in 270 patients].
    Machecourt J; Cassagnes J; Bassand JP; Dumoulin J; Calop J; Foroni L; Terrisse MP; Hénon T; Petit L; Denis B
    Arch Mal Coeur Vaiss; 1993 Feb; 86(2):209-17. PubMed ID: 8363422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.